China Biopharmaceutical's Xie Xin: Medical IPOs to Diverge, Funds to Flow to Targets with Clear BD and Commercialization Prospects | 2026 Medical Industry Outlook - 36 Kr

2026-03-02 - 02:03

China Biopharmaceutical's Xie Xin: Medical IPOs to Diverge, Funds to Flow to Targets with Clear BD and Commercialization Prospects | 2026 Medical Industry Outlook 36 Kr